In Patients with Non-Dysplastic Barrettʼs Esophagus (NDBE), Selective Endoscopic Ablative Therapy (EAT) Based on Risk-Stratification by Molecular Analysis of Mutational Load (ML) is the Most Cost-Effective Management Strategy: 1448

Journal article

Peer reviewed

Ananya Das, Eric Ellsworth, Dennis Smith and Syd Finkelstein

The American journal of gastroenterology, Vol.107, p.S577

10/2012

Metrics

5 Record Views

Title: In Patients with Non-Dysplastic Barrettʼs Esophagus (NDBE), Selective Endoscopic Ablative Therapy (EAT) Based on Risk-Stratification by Molecular Analysis of Mutational Load (ML) is the Most Cost-Effective Management Strategy
Creators: Ananya Das
Eric Ellsworth
Dennis Smith
Syd Finkelstein
Publication Details: The American journal of gastroenterology, Vol.107, p.S577
Identifiers: 991005968840802656
Academic Unit: Internal Medicine
Language: English
Resource Type: Journal article